Study: Single dose of Pfizer vaccine offers LESS protection in cancer patients

Coronavirus, News

Pfizer–BioNTech

Researchers from King’s College London and the Francis Crick Institute found cancer patients with a single dose of the Pfizer jab would have insufficient protection.

The study, which has not yet been peer-reviewed or published, analysed the impact of the vaccine on 151 elderly patients with cancers and 54 volunteers in healthy condition.

It was discovered that one dose of the Pfizer jab provides 39 percent protection for people with cancer after three weeks compared with 97 percent for people without the disease.

The head information nurse at Cancer Research UK, Martin Ledwick said: “This is an interesting study and it’s important to assess how cancer patients are responding to the vaccines being rolled out.”

“But at this stage, we are looking at data that hasn’t been peer-reviewed, where other experts would flag errors and limitations within the results,” he added.

, , , ,

Share:

Similar Posts

Menu